Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Implications for Lorquess From FDA Request for Extremely Large Cardiovascular Outcomes Study for Orexigen's Contrave (ARNA, $1.31)

Stock Opinion
The FDA has shown great reluctance to approve three anti-obesity agents under development: Orexigenís ($2.11, OREX) Contrave, Vivusí ($8.17,…
Read more…

FDA Advisory Committee Vote on Lorcaserin is Negative (ARNA, $3.74)

Yesterday, the FDA advisory committee voted 9 to 5 against approval of Lorcaserin. I listened to the day long proceedings…
Read more…

Trying to Define Path Forward for Lorcaserin with FDA (ARNA,$1.49)

Arena held a conference call on March 11, 2011 to update investors on the possible regulatory path forward for lorcaserin.…
Read more…